DealsPricing

AstraZeneca commits $200 million to Tempus AI in a contract extended through 2031

The amendment sets a $40 million annual spending target with a $32 million yearly floor. Tempus disclosed it in an 8-K filed Nov. 18.

AstraZeneca has committed to pay Tempus AI an aggregate of $200 million in fees from 2027 through 2031, Tempus said in an 8-K filed Nov. 18, 2026.

“establishes a new five-year financial commitment period”

Tempus AI 8-K

The two companies signed a fifth amendment to their 2021 master services agreement on Nov. 16. It takes effect on Jan. 1, 2027, and extends the agreement through Dec. 31, 2031. The filing says the amendment "establishes a new five-year financial commitment period" and extends the strategic collaborator benefits AstraZeneca already gets under the agreement.

The commitment works out to an annual target of $40 million across Tempus's existing and future products and services, with a floor of $32 million in each calendar year. If the full $200 million has not been reached by the end of 2031, the term runs one more year, through 2032, to cover the shortfall. AstraZeneca can still terminate for convenience at any time, but it would owe Tempus whatever remains of the $200 million.

The filing does not break the money down by product. Tempus filed the amendment as an exhibit with some portions redacted as confidential.

The same master services agreement is the vehicle for the oncology foundation model work AstraZeneca, Tempus and Pathos agreed in April 2025. Tempus's quarterly report for the period ended Sept. 30 says that under a related agreement Tempus licenses Pathos a de-identified multimodal dataset to help develop and train the model, and Pathos pays Tempus $200 million in data license fees over three years. That is a separate commitment from the new $200 million.

Status: signed Nov. 16, 2026, effective Jan. 1, 2027, per the company's SEC filing.

What this means: a pharma buyer of Tempus's data and services has locked in a minimum of $32 million a year for five years, with a shortfall payment if it walks away early.

Sources

  1. Tempus AI, Form 8-K filed Nov. 18, 2026
  2. Tempus AI, Form 10-Q for the quarter ended Sept. 30, 2026

Spotted an error? See our corrections policy.

Related